Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study) - Concepedia

Concepedia

Publication | Closed Access

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)

208

Citations

18

References

2002

Year

Werner Poewe, Günther Deuschl, A. Gordin, E.‐R. Kultalahti, M. Leinonen

Acta Neurologica Scandinavica

Abstract

Entacapone is an effective and safe levodopa extender and enhancer, improving the symptomatic efficacy of levodopa in PD and adding to the patients' benefit.

References

	Year	Citations
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE C. D. Marsden, J. D. Parkes The Lancet MedicineParkinson DiseaseNeuropharmacologyRehabilitationNeurology	1977	589
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations U. K. Rinne, Jan Larsen, Å Sidén, Neurology	1998	324
Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients Annals of Neurology	1997	306
Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients John G. Nutt, William R. Woodward, R. M. Beckner, Neurology	1994	246
The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials Dennis B. Gillings, Gary G. Koch Drug Information Journal Clinical Decision-makingClinical Trial ManagementClinical TrialsEducationRandomized Controlled Trial	1991	229
Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial A. H. Rajput, W. R. Wayne Martin, Marie Saint‐Hilaire, Neurology	1997	169
Low‐dose L‐dopa therapy in Parkinson's disease Werner Poewe, Andrew J. Lees, G M Stern Neurology Early Mild ParkinsonPsychiatryMedicineParkinson DiseasePsychopharmacology	1986	163
Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone Erkki Nissinen, Inge‐Britt Lindén, Eija Schultz, Naunyn-Schmiedeberg s Archives of Pharmacology Catechol-o-methyltransferase Inhibitor EntacaponeBiochemistryMedicinePharmacological PropertiesMechanism Of Action	1992	146
Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. Hanna Ruottinen, U. K. Rinne Journal of Neurology Neurosurgery & Psychiatry	1996	144
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients H. Baas, A. G. Beiske, Joseph-André Ghika, Journal of Neurology Neurosurgery & Psychiatry	1997	144

Page 1